Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

Join our team for an expert debrief from ASCO® 2026. With a front-row seat across multiple client engagements, we’ll share the scientific highlights, attendee perspectives and strategic lessons from one of oncology’s most important annual gatherings, while exploring what smarter, more measurable congress engagement looks like in practice.
What we’ll cover
The experts shaping the conversation
This content was provided by Inizio
Latest Content from Inizio
Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver…
PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such…
Authored by Paul Reed and Anabelle Gall
Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its…
Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report…
Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock…
Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk’s Magazine.
Get the insights you need, when you need them, for your product launch planning
The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.
Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.
